New pill shows promise in early hepatitis b trial

NCT ID NCT04536337

First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-stage study tested a new oral drug called ALG-000184 in 165 people, including healthy volunteers and patients with chronic hepatitis B. The main goal was to check if the drug is safe and how the body processes it. Researchers also looked at whether it can lower hepatitis B virus levels, especially when given with a standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ACS

    Auckland, New Zealand

  • CAP Research

    Quatre Bornes, Mauritius, 72218, Mauritius

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA Exploratory Medicine Phase I Unit

    Chisinau, Moldova

  • Prince of Wales

    Shatin, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Saint Vincent's Hospital Melbourne

    Fitzroy, Victoria, 3065, Australia

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016, China

  • Western Health

    Footscray, Victoria, 3011, Australia

Conditions

Explore the condition pages connected to this study.